NKX2-1 and central nervous system cancer: For SOX2, in non-small cell lung cancer, SOX2 works together with the transcription factor NKX2-1 to reshape the tumor's immune microenvironment 28, while in esophageal cancer and adolescent gliomas, SOX2 is considered a potential immunotherapy target 29, 30.